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Tl,e natural history of congenital erythroblastic hypoplasia is well illustrated
by the lifelong observation of the case reported. A unique therapy for trans
fusion l,emosiderosis is reported.-Ed.
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Treatment of Transfusion Hemosiderosis with Desferrioxamine B

,_

Frank J. Hildner, M.D.,* Raymond W. Monto, M.D.,**
and John W. Rebuck, M.D., Ph.D.***
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Periodic case reports of congenital erythroblastic hypoplasia indicate the disease is
well defined. Treatment, however, remains unsatisfactory because therapeutic measures
either fail to induce remission or produce serious side effects. The patient reported
below demonstrates the natural course of the disease and its unresponsiveness to
multiple therapeutic agents. The problems of management will be discussed with special
reference to treatment of transfusion hemosiderosis by a new iron chelating agent.
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A white male child was born at the Henry Ford Hospital in July, 1940, after an un
eventful gestational period. Delivery was normal and birth weight was six pounds, eight ounces.
The immediate neonatal course was uneventful. The patient's growth and development were
normal for the first 18 months. He then began passing frequent bulky foul smelling stools.
Growth and development became retarded, and shortly thereafter he was referred to Henry
Ford Hospital. The impairment of physical development was confirmed and no abnormal
pigmentation, renal anomalies, strabismus or skeletal deformities were noted. Hemoglobin
concentration was found to be 8.8 gm per 100 ml. "Celiac disease" was diagnosed and treat
ment was initiated with a high protein diet. Stools became normal in consistency and less
frequent, while growth and development improved.
However, the anemia was progressive and within six months he was readmitted with
a hemoglobin of 4.2 gm per 100 ml. The white cell count was 5,050 per cubic mm and the
reticulocyte count was 0.1 percent. An apical systolic murmur was interpreted as being
secondary to the anemia. Hypoplasia of the red cell series was noted in the marrow ex
amination, but platelet and white cell production were normal. Blood transfusions were
given, but within a few weeks the hemoglobin concentration again fell. Transfusions subse
quently became necessary every six to ten weeks in order to maintain life.
At age four years, the patient underwent splenectomy at another institution despite
clinical evidence of a normal size spleen and without evidence of excessive hemolysis.
At operation, the spleen was slightly enlarged, but was histologically normal. No thera
peutic benefit resulted, and regular transfusions again became necessary eight weeks after
splenectomy. Various hematinics, including folic acid, vitamin B 12 and iron, were given
without improvement. Four years later, the patient received a full trial of adrenocorti
cotropin therapy without favorable effect. One year later, because of both retarded somatic
development and the suggested erythropoietic effects of androgens, he was treated with
methyl testosterone for several months without success. Pyridoxine and rutin were ad
ministered without objective benefits. Oral corticosteroids were started when he was 14
years of age and have been continued since that time. Repository testosterone therapy was
*Now at Mount Sinai Hospital, Miami Beach, Fla.
**Chief, Hematology Division
***Department of Pathology
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Table of treatments used in case presented.
begun when the patient was 15 years of age and continued to the present time. Dessicated
thyroid also has been continued. Figure I.
Growth and development have always been poor. From age 13 to 15, he grew 3.8
cm. At age 17, bone age was retarded two years and no gonadotropins were recovered
from the urine. Between age 17 and 19 during repository testosterone administration, he
grew at an annual increment of 2.0 cm. AJthough secondary sexual characteristics developed
slowly, the testes have remained prepuberal in size, and potency is very low. Despite inten
sive anabolic hormonal therapy, osteoporosis of the vertebral column was noted in roent
genograms made when the patient was 18 years of age. At this time assay for urinary
gonadotropins failed to detect any, and it was concluded that the patient suffered from
hypophyseal failure.
From age 2 to 18 years, he received repeated blood transfusions, totalling more than
300. Marrow, platelet and white cell counts remained normal while hypoplasia of the red
cell series was repeatedly noted (Fig. 2.) Peripheral smear reticulocyte counts averaged
0.1 percent. He was studied extensively at several other medical centers and these obser
vations were confirmed. Red blood cell fragility and Coombs' tests remained negative.
At age I 6, the patient was found to have an enlarging liver and gradual graying of
color of the skin. Since hemosiderosis was demonstrated in bone marrow, gastric mucosa
(Fig. 3) and liver (Fig. 4), it was concluded that transfusion hemosiderosis was the cause
of the somatic retardation and multisystem failure. During the 17th year of life and
without change of his medical program, the requirements for blood replacement began
to lessen and transfusions were necessary only every four or six months. The reticulocyte
count increased gradually to 1.0 and 2.0 percent, while the bone marrow changed from a
normal cellular marrow with erythroblastic hypoplasia to marked hypercellularity with a
striking increase in normoblasts and the appearance of megaloblasts (Fig. 5). Subsequent
hemoglobin concentrations averaged 10 gm per I 00 ml during this period. His physical
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Figure 2
Aspirate section of marrow. Note- erythroblastic hypoplasia. Dark deposits are hemosiderin .

..

Figure 3
Stomach section. Iron stain reveals pigment in the fundus of gastric glands is hemosiderin.
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Figure 4
Liver section. Iron stain reveals excessive dark deposits of hemosiderin.

Figure 5
Aspirate section of marrow after remission. Note restoration of normal cellularity.
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activity increased. He resumed full time schooling and living approached a near normal
routine. Endocrine replacement was continued without evidence that a specific agent
was responsible for the hematologic remission. The last transfusion was given in January,
I 959. Because severe hemosiderosis was present and since partial hematologic remission
had been firmly established, repeated venesections were done at weekly or biweekly in
tervals in an attempt to reduce total body iron content. It soon became apparent that
venesections in amounts of 50 or 100 ml could not be done without dropping the hemo
globin to critical levels. Therefore, in November, 1962, an attempt to reduce total body
iron stores with the use of desferrioxamine B*, a new iron chelating agent, was under
taken. At that time, the patient's height was 155 cm and weight was 59.5 kilo. He was
weak and short of breath on exertion, remained boyish in appearance, was moderately
obese, and showed pseudogynecomastia, an ashen-gray skin and a tender enlarged liver.
Of the patient's three siblings, two, aged 34 and 36 years, are alive and well. The
third, a brother, had been unsuccessfully treated elsewhere for aplastic anemia. He died
at one year of age, and at postmortem the diagnosis of congenital erythroblastic hypoplasia
was confirmed. No other family member gave a history of anemia or blood disease.
Laboratory Values
Laboratory studies in recent years show a hemoglobin of 8.5 gm per ml, hematocrit 25 per
cent, white blood count 7,400 per cubic mm with normal differential, reticulocyte count
4.3 percent, urinalysis negative, and platelet count 462,000 per cubic mm. Electrophoresis
of serum proteins include total protein 7 .9 gm per ml, albumin 5.50, alpha-1 globulin 0.22,
alpha-2 globulin 0.47, beta globulin 0.98, and gamma globulin 0.73 gm per 100 ml. Bromsul
falein retention is 25 percent in 45 minutes, serum iron is 299 mcg per 100 ml with an
iron binding capacity of 299 mcg per JOO ml. Other chemical determinations are serum
creatinine 0.5 mg per 100 ml, blood urea nitrogen 16 mg per 100 ml, fasting blood sugar
80 mg per 100 ml. Electrocardiogram demonstrates abnormalities compatible with myocarditis.
Discussion
Since 1936, over 75 cases of erythroblastic hypoplasia have been reported in the
literature under the titles of congenital (erythroid) hypoplastic anemia,1 primary red
cell aplasia, erythrogenesis imperfecta, 2 Diamond-Blackfan anemia,3 etc. The disease
usually appears in early neonatal life and has been recognized as early as one or
two months of age. Common abnormalities in the peripheral blood include a hemo
globin of 1.7 to 9.4 gm per 100 ml, a normocytic anemia and reticulocytopenia. Initially,
white blood cells and platelets are normal in quality and quantity, though hypersplenism
may alter this picture later. Bone marrow examination reveals a decreased myeloid
erythroid ratio of 6: 1 to as high as 240: 1, erythroblastic hypoplasia with normal white
blood cell and platelet elements. The response to ordinary modes of therapy is
generally unrewarding, but prognosis is not necessarily poor as long as transfusions
maintain adequate red cell values. With modern clinical procedures the child with
erythroblastic hypoplasia can be expected to survive into the second decade and may
achieve adulthood as the result of transfusion maintenance, corticosteroid therapy,
spontaneous remission or a combination of these.
The case presented demonstrates the familial incidence of this disease as shown
previously by Loeb, Burgert,4 Diamond and others. Unlike Fanconi's anemia, which
has been shown to have autosomal recessive sex-linked transmission, no hereditary
relationship has been established for erythroblastic hypoplasia.5•6
*Desferal, Ciba.
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Treatment

Methods of therapy of this disease fall generally into four categories: A. blood
transfusions, B. empiric hematopoietic stimulation, particularly with corticosteroids,
C. supportive measures, and D. removal of transfusion iron. Transfusion therapy
is the only measure common to all cases which have survived. Regardless of subsequent
course, initial and periodically repeated blood transfusions are needed to support the
anemic circulation. In any chronic blood disorder, careful blood typing and cross
matching is essential to reduce the likelihood of acquired hemolytic anemia, As in
the case presented, the use of sedimented red cells for correction of anemia is advisable.
Whenever therapy has been attempted with hematinic agents, such as iron, folic acid,
B 2, crude liver extract, testosterone, cobalt, or vitamin C, no consistent response has
occurred. Currently, the only well-documented therapeutic hematologic remissions
have occurred in response to adrenocorticotropin or corticosteroid therapy with or
without splenectomy. In the largest series reported, Diamond reports that of 22 patients
treated, 12 encountered steroid induced remission. 7
1

Jeune, 8 Pearson, and others record successfully treated cases, though Loeb9 reports
splenectomy was needed for complete remission. Splenectomy seems to be useful in
isolated cases, but has been inconsistently beneficial when used with steroids, and of
questionable value when employed alone. 3• 0 Expectant management with supportive
therapy is rewarded with remission of the disease in many instances. Our case typifies
the lack of response to hematinics and corticosteroids as well as the unexpected
remission, both of which have occurred in periods from late infancy to early adulthood.
Diamond reports six of his 30 cases had spontaneous remissions while receiving
intermittent transfusions and he mentions four other cases in the Iiterature. 3
1

1

Complications of Treatment

Our case records complications of treatment which occur most frequently in
patients given multiple blood transfusions. Growth retardation, failure of secondary
sexual maturation and osteoporosis (as side effect to corticosteroid therapy) all occur.
Perhaps the most common and serious complication is diffuse increase in iron deposi
tion demonstrated by skin, stomach, heart and liver hemosiderosis. Hemosiderosis with
pigmentation of the skin and enlargement of the liver was noted by Cathie2 and
Lelong 11 in patients with this disease. Liver biopsies performed on patients four and
one-half years old and seven years of age, as well as patients having had long term
blood transfusion maintenance, showed hemosiderin deposits with varying degrees of
fibrosis. In some instances, portal hypertension was present without associated gastro
intestinal bleeding.
Because transfusions are required at monthly or bi-monthly intervals to maintain
life, the amount of iron deposited may amount to 500 mg. of elemental iron a month.
Until remission occurs, which may not be for many years, venesection for the removal
of iron in body stores usually cannot be performed. Although exact measurement is
impossible, we estimate that in over 300 transfusions which our patient received,
more than 40 gm of iron had been deposited in elemental form. Because of the severe
152
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degree of hemosiderosis produced and secondary multiple organ failure, removal of
iron in the total body stores was thought desirable. Venesection was employed for
several months after hematologic remission had occurred, but subsequently was dis
continued because removal of small quantities of blood produced marked lowering
of hemoglobin values.
Treatment With Desferrioxamine 8
In November, 1962, desferrioxamine B, a new iron chelating agent. was utilized
in an attempt to remove iron from the body without producing anemia. Ferrioxamine
is a member of the sideramine family produced by actinomyces fermentation, as are
ferrimycin, albomycin and grisein. Bickel, 12 in 1960, described two new iron containing
compounds, ferrimycin and ferrioxamine B. Clinical trials using ferroxamine B
indicated that when this drug was injected intravenously it would cause a rise in
serum iron concentrations, but the injected iron would not be combined with, or
available for active production of blood. He determined, therefore, that the iron m
the compound was bound quite strongly and before long an iron-reduced complex of
ferrioxamine B was produced, namely desferrioxamine B, which could chelate circulating
trivalent iron. Smith13 points out that in patients with excess storage of iron, significant
urinary iron excretion can be achieved by the parenteral administration of des
ferrioxamine B. His work indicates that patients with oversaturation of the plasma
iron binding capacity will excrete 11 to 40 mg of elemental iron per gram of des
ferrioxamine B. Bannerman 14 points out, however, that in "iron overload" the amount
of iron removed by desferrioxamine B is small compared to that removed by
venesection. Therefore, the latter remains the method of choice for removal of iron.
It has been shown that 1200 mg of desferrioxamine B will remove five mg of iron
daily in normal subjects, 15 mg in persons with secondary hemosiderosis and 50 to
80 mg of iron daily in cases of idiopathic hemochromatosis. 15
Desferrioxamine B therapy was begun on our patient with an initial daily dose
of 1200 mg intravenously (IV) and then 800 mg IV and 400 mg intramuscularly
(IM). This schedule was continued for I I days. The patient was discharged from
the hospital and treatment was continued at home with 400 mg twice daily intra
gluteally. Because of local discomfort, on the 22nd day the dose was reduced to
400 mg once daily which was better tolerated. On the 57th day, in an attempt to
increase iron excretion, the 400 mg dose was increased to 600 mg desferrioxamine B
dissolved in a single injection of 3 ml daily. This dose was tolerated well and was
continued until the 121st day when the 600 mg dose was given every other day to
determine the effect on urinary iron excretion. Since the 200th day, 1000 mg of the drug
has been given daily subcutaneously (SC) without discomfort or other side effects.
Clinical examination during this time revealed marked clearing of the ashen-gray color
of the skin of the patient as well as marked reduction in the size of the liver from
4 to 5 cm below the costal margin to only palpable at the costal margin. An un
explained rise in hemoglobin level to 11.5 gm per LOO ml was noted in the month
after cessation of phlebotomies and institution of desferrioxamine B therapy. However,
the hemoglobin gradually fell to pretreatment levels.
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Figure 6
Results of urinary excretion of iron in response lo desferrioxamine-1:1 administration.

During the period of study, it is estimated 3.5 gm of elemental iron was excreted
in response to treatment. Urinary iron excretion has remained proportional to the
amount of drug administered (Figure 6). An average of 14.7 mg of iron was excreted
daily in response to 1200 mg of desferrioxamine B therapy. Serum iron levels re
mained unchanged until the eighth month of treatment. At that time serum iron fell
from 226 mg per I 00 ml to I 83 mg per 100 ml. Serum iron binding capacity fell
from 233 mg per I 00 ml to 210 mg per I 00 ml. During IM administration, frequency
and total dosage were limited only by local tissue tolerance. For this reason, the IV
route is preferred if higher than 1200 mg single doses are to be given. But if this
dose or Jess is to be administered daily, the SC route is preferred because of its
freedom from discomfort and ease of administration. No systemic side effects directly
related to desferrioxamine B have been observed.
Conclusions

Clinical evidence suggests that reduction of body iron by chelation with des
ferrioxamine B in transfusion hemosiderosis is possible with the duration of treatment
depending on total amount of accumulated body iron. However, it seems that in
cases of anticipated repeated transfusions best results could be obtained with daily
desferrioxamine therapy initiated with the beginning of transfusions. In this way, iron
excretion would possibly equal iron administration, and side effects of hemosiderosis
would be prevented.
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Summary
Transfusion hemosiderosis occurred in a patient with congenital erythroblastic
hypoplasia treated with multiple transfusions. Treatment by venesection was hazardous;
therefore, desferrioxamine B, a new iron chelating agent, was administered and re
moved significant amounts of iron. A description of the results of the therapy and
the case history is presented.
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